DARA BioSciences to Present DB959 At the 'Annual Targeting Diabetes with Novel Therapeutics' Meeting Sponsored by Cambridge Healthtech Institute
14 mai 2009 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 14, 2009 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that the DB959 program has been identified by Cambridge Healthtech Institute ("CHI") for inclusion...
DARA BioSciences Announces Positive Trial Results of KRN5500 for Treatment of Neuropathic Pain in Patients With Cancer
12 mai 2009 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 12, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced positive results from a Phase 2a clinical trial of KRN5500 for treatment of neuropathic pain in...
DARA BioSciences Appoints Gail F. Lieberman to Its Board of Directors
30 avr. 2009 13h00 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., April 30, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced the appointment of Gail F. Lieberman to its Board of Directors. The appointment was effective April 27,...
DARA BioSciences, Inc. Announces Going Concern and NASDAQ Notice
10 avr. 2009 17h00 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., April 10, 2009 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA) ("DARA" or the "Company"), a development-stage pharmaceutical company, announced today that the audit report...
DARA BioSciences to Present Abstracts for DB959 At American Diabetes Association Scientific Sessions
30 mars 2009 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 30, 2009 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that two abstracts have been accepted for presentation at the annual American Diabetes...
United States Food and Drug Administration ('FDA') Approves DARA Investigational New Drug Application ('IND') for DB959 -- An Oral Medication Intended for the Treatment of Type 2 Diabetes
10 mars 2009 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 10, 2009 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA), today announced that the United States Food and Drug Administration ("FDA") has cleared the Company's...
DARA Raises $1,000,000 in New Capital
05 févr. 2009 07h45 HE
|
DARA BioSciences, Inc.
Richard A. Franco, Sr. Appointed as Chief Executive Officer and Director
DARA Files Investigational New Drug Application ("IND") With the United
States Food and Drug Administration...
DARA BioSciences Raises $2,255,000 Through the Sale of Common Stock and Warrants
21 oct. 2008 17h58 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Oct. 21, 2008 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company focused on compounds designed to address diabetes, neuropathic pain...
DARA BioSciences Announces Completion of Toxicology Studies for Its PPAR-delta/gamma Agonist, DB959
02 oct. 2008 09h18 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Oct. 2, 2008 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company, announced the completion of all toxicology studies necessary for...
DARA BioSciences Plans to Restate Financial Statements for the Quarter Ended March 31, 2008 to Reflect Increased Valuation of Investment
14 août 2008 18h22 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Aug. 14, 2008 (PRIME NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) reported today that it expects to restate its financial statements for the quarter ended March 31, 2008, to...